-
公开(公告)号：US20120294870A1
公开(公告)日：2012-11-22
申请号：US13549633
申请日：2012-07-16
IPC分类号： C07K16/24 , A61K39/395 , C40B30/00 , G01N33/566 , C12Q1/68 , C12N5/18 , G01N33/577 , G01N21/76 , C12N15/13 , C12N15/63 , C12N1/21 , C12N1/19 , C12N5/10 , A61P35/00 , C12N5/09
CPC分类号： C07K16/2848 , A61K38/00 , A61K2039/505 , C07K16/18 , C07K16/24 , C07K16/2884 , C07K16/40 , C07K2317/76 , G01N33/57438 , G01N33/57484 , G01N2333/52
摘要： Based on the observation of the cooperation of osteopontin (OPN) and matrixmetalloproteinase-9 (MMP-9) in the promotion of the metastatic phenotype, therapies and diagnostic assays are disclosed for the treatment of a tumor that overexpresses OPN, such as hepatocellular carcinoma (HCC), for example metastatic HCC. In one example, methods of treating a tumor include administration of an agent that reduces cellular invasion resulting from the interaction between a fragment of OPN (OPN-5kD) generated by MMP-9 cleavage and CD44 receptor. Examples of such agents include fragments of OPN-5kD and antibodies specific for OPN-5kD. Therapeutic compositions are also provided that include such agents. Also provided are methods of diagnosing or prognosing a tumor, for example by detecting expression of OPN-5kD peptide or OPN-c mRNA in a biological sample obtained from the subject. Also provided are antibodies that specifically bind OPN-5kD.
摘要翻译： 基于骨桥蛋白（OPN）和基质金属蛋白酶-9（MMP-9）在促进转移表型中的合作观察，公开了治疗和过度表达OPN的肿瘤如肝细胞癌（ HCC），例如转移性HCC。 在一个实例中，治疗肿瘤的方法包括施用减少由MMP-9切割产生的OPN片段（OPN-5kD）与CD44受体之间的相互作用而引起的细胞侵袭的药剂。 这些试剂的实例包括OPN-5kD片段和OPN-5kD特异性抗体。 还提供包括这些试剂的治疗组合物。 还提供了诊断或预后肿瘤的方法，例如通过检测从受试者获得的生物样品中OPN-5kD肽或OPN-cmRNA的表达。 还提供了特异性结合OPN-5kD的抗体。
-
公开(公告)号：US08568977B2
公开(公告)日：2013-10-29
申请号：US13549633
申请日：2012-07-16
申请人： Vivian Takafuji , Xin Wei Wang , Paul K. Goldsmith
发明人： Vivian Takafuji , Xin Wei Wang , Paul K. Goldsmith
CPC分类号： C07K16/2848 , A61K38/00 , A61K2039/505 , C07K16/18 , C07K16/24 , C07K16/2884 , C07K16/40 , C07K2317/76 , G01N33/57438 , G01N33/57484 , G01N2333/52
摘要： Based on the observation of the cooperation of osteopontin (OPN) and matrixmetalloproteinase-9 (MMP-9) in the promotion of the metastatic phenotype, therapies and diagnostic assays are disclosed for the treatment of a tumor that overexpresses OPN, such as hepatocellular carcinoma (HCC), for example metastatic HCC. In one example, methods of treating a tumor include administration of an agent that reduces cellular invasion resulting from the interaction between a fragment of OPN (OPN-5kD) generated by MMP-9 cleavage and CD44 receptor. Examples of such agents include fragments of OPN-5kD and antibodies specific for OPN-5kD. Therapeutic compositions are also provided that include such agents. Also provided are methods of diagnosing or prognosing a tumor, for example by detecting expression of OPN-5kD peptide or OPN-c mRNA in a biological sample obtained from the subject. Also provided are antibodies that specifically bind OPN-5kD.
摘要翻译： 基于骨桥蛋白（OPN）和基质金属蛋白酶-9（MMP-9）在促进转移表型中的合作观察，公开了治疗和过度表达OPN的肿瘤如肝细胞癌（ HCC），例如转移性HCC。 在一个实例中，治疗肿瘤的方法包括施用减少由MMP-9切割产生的OPN片段（OPN-5kD）与CD44受体之间的相互作用而引起的细胞侵袭的药剂。 这些试剂的实例包括OPN-5kD片段和OPN-5kD特异性抗体。 还提供包括这些试剂的治疗组合物。 还提供了诊断或预后肿瘤的方法，例如通过检测从受试者获得的生物样品中OPN-5kD肽或OPN-cmRNA的表达。 还提供了特异性结合OPN-5kD的抗体。
-
公开(公告)号：US08247183B2
公开(公告)日：2012-08-21
申请号：US12871669
申请日：2010-08-30
申请人： Vivian Takafuji , Xin Wei Wang , Paul K. Goldsmith
发明人： Vivian Takafuji , Xin Wei Wang , Paul K. Goldsmith
IPC分类号： G01N33/53
CPC分类号： C07K16/2848 , A61K38/00 , A61K2039/505 , C07K16/18 , C07K16/24 , C07K16/2884 , C07K16/40 , C07K2317/76 , G01N33/57438 , G01N33/57484 , G01N2333/52
摘要： Based on the observation of the cooperation of osteopontin (OPN) and matrixmetalloproteinase-9 (MMP-9) in the promotion of the metastatic phenotype, therapies and diagnostic assays are disclosed for the treatment of a tumor that overexpresses OPN, such as hepatocellular carcinoma (HCC), for example metastatic HCC. In one example, methods of treating a tumor include administration of an agent that reduces cellular invasion resulting from the interaction between a fragment of OPN (OPN-5kD) generated by MMP-9 cleavage and CD44 receptor. Examples of such agents include fragments of OPN-5kD and antibodies specific for OPN-5kD. Therapeutic compositions are also provided that include such agents. Also provided are methods of diagnosing or prognosing a tumor, for example by detecting expression of OPN-5kD peptide or OPN-c mRNA in a biological sample obtained from the subject. Also provided are antibodies that specifically bind OPN-5kD.
摘要翻译： 基于骨桥蛋白（OPN）和基质金属蛋白酶-9（MMP-9）在促进转移表型中的合作观察，公开了治疗和过度表达OPN的肿瘤如肝细胞癌（ HCC），例如转移性HCC。 在一个实例中，治疗肿瘤的方法包括施用减少由MMP-9切割产生的OPN片段（OPN-5kD）与CD44受体之间的相互作用而引起的细胞侵袭的药剂。 这些试剂的实例包括OPN-5kD片段和OPN-5kD特异性抗体。 还提供包括这些试剂的治疗组合物。 还提供了诊断或预后肿瘤的方法，例如通过检测从受试者获得的生物样品中OPN-5kD肽或OPN-cmRNA的表达。 还提供了特异性结合OPN-5kD的抗体。
-
公开(公告)号：US20090136524A1
公开(公告)日：2009-05-28
申请号：US12340211
申请日：2008-12-19
IPC分类号： A61K39/395 , G01N33/68 , G01N33/53 , C12Q1/02 , A61K38/10 , C07K14/435 , C07H21/00 , A61P35/00 , C12N15/63 , C07K16/00 , A61K38/17 , A61K38/08 , C12Q1/68 , C12N5/00
CPC分类号： C07K16/2848 , A61K38/00 , A61K2039/505 , C07K16/18 , C07K16/24 , C07K16/2884 , C07K16/40 , C07K2317/76 , G01N33/57438 , G01N33/57484 , G01N2333/52
摘要： Based on the observation of the cooperation of osteopontin (OPN) and matrixmetalloproteinase-9 (MMP-9) in the promotion of the metastatic phenotype, therapies and diagnostic assays are disclosed for the treatment of a tumor that overexpresses OPN, such as hepatocellular carcinoma (HCC), for example metastatic HCC. In one example, methods of treating a tumor include administration of an agent that reduces cellular invasion resulting from the interaction between a fragment of OPN (OPN-5kD) generated by MMP-9 cleavage and CD44 receptor. Examples of such agents include fragments of OPN-5 kD and antibodies specific for OPN-5kD. Therapeutic compositions are also provided that include such agents. Also provided are methods of diagnosing or prognosing a tumor, for example by detecting expression of OPN-5kD peptide or OPN-c mRNA in a biological sample obtained from the subject. Also provided are antibodies that specifically bind OPN-5kD.
摘要翻译： 基于骨桥蛋白（OPN）和基质金属蛋白酶-9（MMP-9）在促进转移表型中的合作观察，公开了治疗和过度表达OPN的肿瘤如肝细胞癌（ HCC），例如转移性HCC。 在一个实例中，治疗肿瘤的方法包括施用减少由MMP-9切割产生的OPN片段（OPN-5kD）与CD44受体之间的相互作用而引起的细胞侵袭的药剂。 这些试剂的实例包括OPN-5kD片段和OPN-5kD特异性抗体。 还提供包括这些试剂的治疗组合物。 还提供了诊断或预后肿瘤的方法，例如通过检测从受试者获得的生物样品中OPN-5kD肽或OPN-cmRNA的表达。 还提供了特异性结合OPN-5kD的抗体。
-
公开(公告)号：US07803380B2
公开(公告)日：2010-09-28
申请号：US12340211
申请日：2008-12-19
申请人： Vivian Takafuji , Xin Wei Wang
发明人： Vivian Takafuji , Xin Wei Wang
CPC分类号： C07K16/2848 , A61K38/00 , A61K2039/505 , C07K16/18 , C07K16/24 , C07K16/2884 , C07K16/40 , C07K2317/76 , G01N33/57438 , G01N33/57484 , G01N2333/52
摘要： Based on the observation of the cooperation of osteopontin (OPN) and matrixmetalloproteinase-9 (MMP-9) in the promotion of the metastatic phenotype, therapies and diagnostic assays are disclosed for the treatment of a tumor that overexpresses OPN, such as hepatocellular carcinoma (HCC), for example metastatic HCC. In one example, methods of treating a tumor include administration of an agent that reduces cellular invasion resulting from the interaction between a fragment of OPN (OPN-5kD) generated by MMP-9 cleavage and CD44 receptor. Examples of such agents include fragments of OPN-5kD and antibodies specific for OPN-5kD. Therapeutic compositions are also provided that include such agents. Also provided are methods of diagnosing or prognosing a tumor, for example by detecting expression of OPN-5kD peptide or OPN-c mRNA in a biological sample obtained from the subject. Also provided are antibodies that specifically bind OPN-5kD.
摘要翻译： 基于骨桥蛋白（OPN）和基质金属蛋白酶-9（MMP-9）在促进转移表型中的合作观察，公开了治疗和过度表达OPN的肿瘤如肝细胞癌（ HCC），例如转移性HCC。 在一个实例中，治疗肿瘤的方法包括施用减少由MMP-9切割产生的OPN片段（OPN-5kD）与CD44受体之间的相互作用而引起的细胞侵袭的药剂。 这些试剂的实例包括OPN-5kD片段和OPN-5kD特异性抗体。 还提供包括这些试剂的治疗组合物。 还提供了诊断或预后肿瘤的方法，例如通过检测从受试者获得的生物样品中OPN-5kD肽或OPN-cmRNA的表达。 还提供了特异性结合OPN-5kD的抗体。
-
-
-
-
搜索结果
5 条记录 (耗时 0.029 秒)
